Latest Content

Psychiatrists push to normalize sexual health talks, address medication-related sexual side effects, and reduce stigma with holistic care and patient-safe communication.

Brain capital drives competitiveness—see how ROI-focused mental health care and responsible AI expand access, build resilience, and boost productivity.

PMN310 shows strong 6‑month safety in early Alzheimer disease, with zero ARIA‑E and encouraging tau biomarker shifts before 2027 data.

Northwestern researchers identify a reduced CSF protein signal in schizophrenia and show a synthetic version restores brain circuit activity in mice.

Why teens use drugs and alcohol: avoidant attachment and emotional isolation fuel addiction; attachment-based therapy rebuilds bonds and cuts relapse.

Clinical AI in psychiatry falters when designers miss ward realities; better ethnographic UX research reduces alert fatigue, cognitive load, and boosts meaningful adoption.

New analysis shows COMP360 psilocybin sessions for PTSD stay mostly silent, with nondirective support boosting safety and autonomy.

Phase 2 ZEPHYR finds oral betovumeline combo reduces PANSS and improves cognition in acute schizophrenia, with generally mild side effects.

After TBI, soluble TNF sparks Alzheimer-like damage; XPro1595 blocks it in mice, preserving memory and reducing pain—hinting prevention.

FDA clears Simtriyo, a first-in-class NDSRI and central nervous system stimulant for ADHD, offering new symptom and executive-function gains.

New BEST teletraining helps people after TBI name emotions, reduce anxiety and anger, and boost resilience—early trials show promise.

Placebo and nocebo effects shape psychiatric care—how expectations and framing boost medication benefit and reduce side effects.

Don't miss out on these CME articles! Test your knowledge here.